Discontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution.

Nuno Cerveira,Bruno Loureiro,Susana Bizarro,Cecília Correia,Lurdes Torres,Susana Lisboa,Joana Vieira,Rui Santos,Dulcineia Pereira,Cláudia Moreira,Sérgio Chacim,Nélson Domingues,Ana Espírito-Santo,Isabel Oliveira,Ilídia Moreira,Luísa Viterbo,Ângelo Martins,Manuel R Teixeira,José M Mariz

BMC cancer（2018）

引用 15|浏览28

暂无评分

摘要

Our results suggest that TKI discontinuation is safe outside clinical trials and particularly effective in CML patients who are in SDMR with longer TKI treatment duration.

查看译文

关键词

Chronic myeloid leukemia,TKI discontinuation,TKI therapy duration,Sustained deep molecular response,Unsustained deep molecular response

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要